Table 3.

Treatment parameters of patients with dyspnoeic and silent hypoxia

	Dyspnoeic hypoxia			Non-dyspnoeic (silent) hypoxia
	Available for	Available observations (N)	n (col %)	Available observations (N)	n (col %)	P
HFNC	792	624	100 (16.03%)	168	16 (9.52%)	0.034
NIV	806	633	179 (28.28%)	173	36 (20.81%)	0.049
IMV	810	637	170 (26.69%)	173	41 (23.7%)	0.427
Either NIV or IMV	811	637	228 (35.79%)	174	52 (29.89%)	0.146
Steroids	809	635	583 (91.81%)	174	157 (90.23%)	0.508
Methylprednisolone Pulse	762	612	128 (20.92%)	150	13 (8.67%)	0.001
Anticoagulants	793	632	557 (88.13%)	161	128 (79.5%)	0.004
Inhaled Steroids	767	616	194 (31.49%)	151	29 (19.21%)	0.003
Ivermectin	762	613	100 (16.31%)	149	27 (18.12%)	0.595
Doxycycline	763	613	140 (22.84%)	150	35 (23.33%)	0.897
Minocycline	763	613	18 (2.94%)	150	7 (4.67%)	0.286
Azithromycin	762	612	107 (17.48%)	150	28 (18.67%)	0.734
Ceftriaxone	763	613	174 (28.38%)	150	35 (23.33%)	0
Levofloxacin	765	615	161 (26.18%)	150	16 (10.67%)	0
Tocilizumab	770	619	23 (3.72%)	151	8 (5.3%)	0.375
Remdesivir	770	616	232 (37.66%)	154	57 (37.01%)	0.882
Zinc	729	584	163 (27.91%)	145	37 (25.52%)	0.563
In-Hospital complications
Hyperglycaemia	704	566	221 (39.05%)	138	49 (35.51%)	0.443
Renal Dysfunction	741	584	166 (28.42%)	157	51 (32.48%)	0.321
Hypotension	797	628	55 (8.76%)	169	20 (11.83%)	0.224
Hospital Acquired Infection	47	39	26 (66.67%)	8	6 (75%)	0.645
Critical illness	811	637	232 (36.42%)	174	56 (32.18%)	0.301
Final Outcome	811
Discharges			382 (59.97%)		95 (54.6%)	0.202
Deaths			255 (40.03%)		79 (45.4%)

*HFNC- High-flow nasal cannula, NIV- Non-invasive ventilation, IMV- Invasive mechanical ventilation